Clinical Trial Search

Primary: Standardized Area Under the Curve (AUC) for VEGF A Levels by SIMOA (Quanterix's Single Molecule Array) Method for the Comparative Phase — 18.78; 33.95 pg/mL — p=<0.0001

Primary: Number of Participants With Progression Free Survival (PFS=Date of Progression of Disease or Death) at 6 Months Using Bevacizumab, Carboplatin, and Paclitaxel in…

Primary: Number of Participants With Graft Failure at Week 39 and 52 — 0; 1; 1; 1 Participants

Primary: Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 24 With Discontinued Participants…

Primary: Percent Change From Baseline at Month 3 in Plasma VEGF Following Intravitreal (IVT) Injection of Anti-VEGF Agent — 41.04; -21.53 Percent change — p=0.012

Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 12 — 6.8; 8.5; 8.8…

Primary: Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence…

Primary: Vascular Endothelial Growth Factor Levels — 73.46 pg/ml

Primary: Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events)) — 6; 6; 6; 12 Participants

Primary: 6 Month Progression-free Survival — 18 participants

Primary: Percentage of Participants Who Gained at Least 15 Letters in BCVA at Week 24 as Measured by ETDRS Letter Score — 64; 9 percentage of participants — p=< 0.0001

Primary: Percent Change From Baseline in Urinary Albumin-to-creatinine Ratio (ACR) — 3.2; 17.7; 5.4 Geometric Mean of Percent Change — p=0.485

Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 12 — 5.2; 5.6; 5.4…

Primary: FAZ Area Change — 0.03 mm^2

Primary: Development of PDR and/or DME (Whichever Came First) — 27; 75 Eyes

Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA

Primary: Tabulation of Adverse Events — 13 adverse events

Primary: Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) — 94.42; 95.62; 96.27; 95.56 Percentage of participants

Primary: Visual Acuity: Percentage of Patients Losing 3 or More Lines(15 Letters) of Visual Acuity From Baseline. — 80; 90 percent of participants

Primary: Change in Volume Ipsilateral Lymphedema in Arm — -161.0; -372.8 mL — p=0.0658

Primary: Mean Visual Acuity Change — 5.6; 5.8 ETDRS letters

Primary: Change in Late Outgrowth Endothelial Progenitor Colonies — 0.3; 0.2; 3.1; 0.1 LOEPC colonies — p=<0.05

Primary: Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) — 94.4; 95.1; 95.9; 95.1 percentage of patients

Primary: VEGF Protein and mRNA Levels — 1395; 1069; 1666 pg/ml — p=<0.001

Primary: Heart Rate — 68.7 Beats per Minutes

Primary: Tumor Resolution — 25 Participants

Primary: Change From Baseline in Plasma Vascular Endothelial Growth Factor (VEGF) Concentration After First Injection at Visit 5 (Day 8 +/- 1 Day) — 5.720; -25.833 pg/mL

Primary: Change in ETDRS Best Corrected Visual Acuity From Baseline at 54 Weeks — 14 ETDRS letters

Primary: Adverse Events (Ocular and Systemic) — 0 participants

Primary: Effect of Vitamin D on Angiogenic Factors — 6.7; 5.6; 5.9; 5.5 ratio